Six novel compounds have been synthesized combining pharmacological potential of benzimidazole and schiff’s bases ring. A new series of substituted benzimidazole derivative 3a-3f were synthesized by cyclocondensation of 4-(2-(1H-benzo[d]imidazol-1-yl)-2-oxoethyl)semicarbazide with  various aryl benzaldehyde derivatives. The newly synthesized compounds were characterized by IR, MASS and ¹H NMR spectral data. The synthesized compounds were evaluated for in vitro anti-cancer activity by MTT assay. Compound (3f) exhibited significant cytotoxicity was observed against HeLa cell line with IC₅₀ value in the range of 6.13 µM respectively.

The five different types of pyrazine derivatives were synthesized called as 5-methylpyrazine-2-carbohydrazide. The structures of the synthesized compounds were characterized on the basis of IR, ¹hnmr and Mass spectral data. Among all synthesized compounds all compounds are screened for their anti-inflammatory activity by paw edema method, Diclofenac sodium is employed as a reference standard, the percentage inhibition of pyrazine derivatives and diclofenac were 96.71 % and 98.68 % respectively. From the results it is concluded that, compound II and V exhibited potent, when compare to rest of compounds exhibited mild to moderate anti inflammatory activity.

Targeting drug delivery into the lungs has become one of the most important aspects of systemic or local drug delivery. Consequently, in the last few years, techniques and new drug delivery devices intended to deliver drugs into the lungs have been widely developed. Currently, the main drug targeting regimens include direct application of a drug into the lungs, mostly by inhalation therapy using either pressurized metered dose inhalers (pMDI) or dry powder inhalers (DPI). Intratracheal administration is commonly used as a first approach in lung drug delivery in vivo. To convey a sufficient dose of drug to the lungs, suitable drug carriers are required. These can be solid, liquid, or gaseous excipients. Liposomes, nano and microparticles, cyclodextrins, microemulsions, micelles, suspensions, or solutions are all examples of this type of pharmaceutical carrier that have been successfully used to target drugs into lungs. The use of micro reservoir type systems offers clear advantages, such as high loading capacity and possibility of controlling size and permeability, and thus of controlling the release kinetics of the drugs from the carrier systems. These systems make it possible to use relatively small numbers of vector molecules to deliver substantial amounts of a drug to the target. This review prominently describes the formulation approaches and devices required to be administer drug into the lungs.

Nanomedicine has emerged as one of the very promising fields of pharmaceutical research in the last few decades. Drug delivery is one of the areas where this technology has made remarkable progress. The present article is an attempt to present the brief history of Nanomedicine and market forecasts about Nanomedicine. The article presents the composition, classification, advantages and examples of Nanomedicine assisted drug delivery. Developments in Nanomedicine assisted therapeutic applications and the future prospects have also been discussed. The drug can be released at the specific target site instead of circulating throughout the body it will be more effective for a particular given dosage.